sarcoma
dr Jonathan C. Trent, a medical oncologist specializing in sarcoma and connective tissue medical oncology at Sylvester, is available to discuss a wide range of issues related to sarcoma research and experimental therapeutics. He and his staff are involved in several ASCO23 presentations including:
While in Chicago, but not as part of ASCO, he will also present a CME for tumor-agnostic precision oncology.
==
Mesothelioma, Lung Cancer and Global Oncology (B-Roll/Video Available)
dr Gilberto Lopes, a medical thoracic oncologist, is chief of medical oncology, medical director for international programs and associate director for global oncology at Sylvester. He is Editor-in-Chief of the Journal of Global Oncology, the premier source for global oncology studies. dr Lopes is available to discuss a wide range of topics related to mesothelioma and lung cancer research, as well as global health and the ATOM Coalition. He and his collaborators are involved in several ASCO23 abstract presentations, posters and publications. Downloadable b-rolls/videos can be found here.
==
prostate cancer
dr Marijo Bilusic leads Sylvester’s Genitourinary Cancers Site Disease Group, where he treats urogenital tumors (adrenal, kidney, prostate, bladder, and testicles). His current research interests are focused on tumor immunology and the development of novel immunotherapy approaches for prostate cancer and other urogenital tumors using therapeutic cancer vaccines, antibodies, immunomodulators or immune checkpoint inhibitors, not only as monotherapies but in combination with other therapies as part of a programmatic effort in the field of immuno-oncology. He is board certified in medical oncology, hematology and internal medicine and is available to discuss abstracts, presentations and research results related to urogenital cancer.
==
Breast Cancer and Breast Cancer Surgery (B-Roll/Video Available)
dr Kristin E. Rojas is a Sylvester breast cancer surgeon and board-certified gynecologic surgeon. She is one of the few dual-trained physicians with expertise in both breast cancer surgery and women’s sexual health. Her research interests include the impact of perioperative opioids on the gut microbiome, decision making during breast cancer surgery, and women’s sexual health after cancer. She is a national leader in treating sexual dysfunction in women with cancer and an expert in treating menopausal symptoms in women with cancer, optimizing the sexual health of women who have survived cancer, and minimizing the need for redundant opioid prescriptions during cancer surgery. At ASCO23, she will lead A Juggling Act: Managing the Toxicity of Estrogen Deprivation for Patients With Breast Cancer, a dedicated educational event addressing quality of life for patients receiving endocrine therapy for breast cancer, advances in breast cancer Improving sexual health, maintaining fertility, and bone health. Downloadable b-rolls/videos can be found here.
==
melanoma
Florida has the second highest incidence of melanoma in the United States. dr Based in Miami, Jose Lutzky leads Cutaneous Oncology Services at Sylvester and is Director of the Clinical Trials Coordinating Unit. Triple board certified in hematology, oncology and internal medicine, he is part of a multidisciplinary team of cancer experts and researchers focused on finding new and better treatment options.
==
Gastrointestinal (GI) Cancer (B-Roll/Video Available)
dr Shria Kumar is a Clinical Epidemiologist and Gastroenterologist. As a member of Sylvester’s Cancer Control Program, her research focuses on the screening, early detection and early treatment of gastrointestinal cancer, and the identification and amelioration of cancer differences. dr Kumar is a recipient of ASCO’s 2023 Conquer Cancer Career Development Award. With this funding, she plans to explore the impact of weight gain on colorectal cancer risk and mortality in a diverse patient population. Kumar also plans to develop a comparative analysis of body mass index and body composition measurements to better guide physicians who use weight loss interventions in their patients. Downloadable b-rolls/videos can be found here.
==
Thyroid Cancer (B-Roll/Video Available)
Historically, surgery has been the first line of treatment for patients with thyroid cancer. Now, with targeted therapies and other new drugs emerging, surgery could become more of a secondary option for certain patients if those treatments fail. This new context could potentially change the way some procedures are performed. The Sylvester ENT doctor and head and neck surgeon Dr. Zoukaa Sargi will participate in an ASCO panel discussion on treating thyroid cancer on June 2nd. Sargi specializes in head and neck cancer and will discuss the evolution of thyroid cancer treatment from a surgeon’s perspective. Downloadable b-rolls/videos can be found here.
==
Solid and CNS tumors
dr Macarena de la Fuente, director of neuro-oncology at Sylvester, whose research focus is developing treatments for primary brain tumors, will present results from a Phase 1/2a study evaluating the safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid tumors and tumors of the central nervous system. The study showed that the experimental, targeted therapy could be effective in treating BRAF-altered solid tumors, including previously untargeted mutations, with a benign safety profile. The study targeted a wide range of cancer types including high grade glioma, low grade glioma, colorectal cancer, papillary thyroid cancer, melanoma, pancreatic cancer, ovarian cancer, non-small cell lung cancer, anaplastic thyroid cancer and others.
# # #
